State Street’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49.1M | Sell |
259,116
-13,898
| -5% | -$2.61M | ﹤0.01% | 1850 |
|
|
2026
Q1 | $53.8M | Sell |
273,014
-148,065
| -35% | -$28.5M | ﹤0.01% | 1704 |
|
|
2025
Q4 | $77.4M | Sell |
421,079
-62,496
| -13% | -$11M | ﹤0.01% | 1494 |
|
|
2025
Q3 | $74.2M | Buy |
483,575
+14,076
| +3% | +$2.13M | ﹤0.01% | 1524 |
|
|
2025
Q2 | $65.6M | Sell |
469,499
-29,779
| -6% | -$4.17M | ﹤0.01% | 1537 |
|
|
2025
Q1 | $73.4M | Sell |
499,278
-100,613
| -17% | -$14.6M | ﹤0.01% | 1438 |
|
|
2024
Q4 | $78.6M | Sell |
599,891
-308,921
| -34% | -$43.2M | ﹤0.01% | 1492 |
|
|
2024
Q3 | $142M | Sell |
908,812
-255,958
| -22% | -$41.3M | 0.01% | 1120 |
|
|
2024
Q2 | $182M | Sell |
1,164,770
-192,981
| -14% | -$29M | 0.01% | 914 |
|
|
2024
Q1 | $184M | Buy |
1,357,751
+583,844
| +75% | +$77.3M | 0.01% | 911 |
|
|
2023
Q4 | $104M | Buy |
773,907
+78,009
| +11% | +$10.1M | 0.01% | 1265 |
|
|
2023
Q3 | $94.3M | Buy |
695,898
+72,291
| +12% | +$9.87M | 0.01% | 1222 |
|
|
2023
Q2 | $89.3M | Sell |
623,607
-415,422
| -40% | -$61.1M | ﹤0.01% | 1300 |
|
|
2023
Q1 | $144M | Buy |
1,039,029
+261,679
| +34% | +$35.2M | 0.01% | 956 |
|
|
2022
Q4 | $105M | Sell |
777,350
-91,565
| -11% | -$11.5M | 0.01% | 1128 |
|
|
2022
Q3 | $95.3M | Buy |
868,915
+153,739
| +21% | +$19.5M | 0.01% | 1129 |
|
|
2022
Q2 | $94.5M | Sell |
715,176
-105,174
| -13% | -$13.8M | 0.01% | 1197 |
|
|
2022
Q1 | $109M | Sell |
820,350
-23,430
| -3% | -$2.81M | 0.01% | 1230 |
|
|
2021
Q4 | $98.3M | Buy |
843,780
+66,439
| +9% | +$7.82M | ﹤0.01% | 1308 |
|
|
2021
Q3 | $93.4M | Buy |
777,341
+657,406
| +548% | +$76.5M | ﹤0.01% | 1318 |
|
|
2021
Q2 | $14.4M | Sell |
119,935
-25,348
| -17% | -$2.78M | ﹤0.01% | 2704 |
|
|
2021
Q1 | $14.4M | Sell |
145,283
-82,185
| -36% | -$8.26M | ﹤0.01% | 2553 |
|
|
2020
Q4 | $22.8M | Buy |
227,468
+191,415
| +531% | +$20.3M | ﹤0.01% | 2174 |
|
|
2020
Q3 | $3.95M | Sell |
36,053
-9,645
| -21% | -$1.07M | ﹤0.01% | 2900 |
|
|
2020
Q2 | $4.83M | Buy |
45,698
+2,704
| +6% | +$279K | ﹤0.01% | 2775 |
|
|
2020
Q1 | $3.84M | Buy |
42,994
+13,147
| +44% | +$1.24M | ﹤0.01% | 2756 |
|
|
2019
Q4 | $2.98M | Sell |
29,847
-72,903
| -71% | -$6.86M | ﹤0.01% | 3093 |
|
|
2019
Q3 | $9.16M | Sell |
102,750
-42,968
| -29% | -$3.73M | ﹤0.01% | 2516 |
|
|
2019
Q2 | $12M | Sell |
145,718
-49,872
| -25% | -$3.91M | ﹤0.01% | 2408 |
|
|
2019
Q1 | $15.9M | Sell |
195,590
-64,906
| -25% | -$5.12M | ﹤0.01% | 2200 |
|
|
2018
Q4 | $19.8M | Buy |
260,496
+79,838
| +44% | +$6.23M | ﹤0.01% | 1990 |
|
|
2018
Q3 | $14.3M | Buy |
180,658
+37,356
| +26% | +$2.83M | ﹤0.01% | 2401 |
|
|
2018
Q2 | $10.1M | Buy |
143,302
+15,175
| +12% | +$1.09M | ﹤0.01% | 2537 |
|
|
2018
Q1 | $8.96M | Buy |
128,127
+4,471
| +4% | +$310K | ﹤0.01% | 2513 |
|
|
2017
Q4 | $8.58M | Buy |
123,656
+36,605
| +42% | +$2.47M | ﹤0.01% | 2531 |
|
|
2017
Q3 | $5.9M | Sell |
87,051
-126,155
| -59% | -$7.97M | ﹤0.01% | 2715 |
|
|
2017
Q2 | $14.5M | Buy |
+213,206
| New | +$13.9M | ﹤0.01% | 2201 |
|
Other funds holding AZN
EP
IA
State Street's AZN Position: Q2 2026 in Review
State Street reduced its AstraZeneca (AZN) stake by 5.1% in Q2 2026, selling an estimated $2.61M and leaving 259,116 shares worth $49.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1850.
State Street first reported a position in AZN in Q2 2017 and has held it in 37 quarters since. The position peaked at $184M in Q1 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- State Street held 259,116 shares of AstraZeneca worth $49.1M as of Q2 2026.
- State Street sold 13,898 AstraZeneca shares in Q2 2026, an estimated $2.61M.
- AstraZeneca made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1850 holding.
- State Street first reported a position in AstraZeneca in Q2 2017 and has held it in 37 quarters since.
- State Street's AstraZeneca position peaked at $184M in Q1 2024.
- 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.